LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Medtronic PLC

Suletud

SektorTervishoid

87.41 0.59

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

86.78

Max

87.43

Põhinäitajad

By Trading Economics

Sissetulek

16M

1.3B

Müük

-111M

8.3B

P/E

Sektori keskmine

23.197

51.198

Aktsiakasum

1.62

Dividenditootlus

3.39

Kasumimarginaal

15.605

Töötajad

95,000

EBITDA

-42M

2.4B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+10.07% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.39%

2.40%

Järgmine tulemuste avaldamine

19. aug 2025

Järgmine dividendimakse kuupäev

11. juuli 2025

Järgmine aktsia dividendi kuupäev (ex-date)

27. juuni 2025

Turustatistika

By TradingEconomics

Turukapital

-13B

107B

Eelmine avamishind

86.82

Eelmine sulgemishind

87.41

Uudiste sentiment

By Acuity

26%

74%

68 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

Medtronic PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. mai 2025, 11:38 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Medtronic Boosts Dividend, Plans to Separate Diabetes Business and Targets Revenue Growth for Year

18. veebr 2025, 12:24 UTC

Tulu

Medtronic 3Q Revenue Rises on Strength in Cardiovascular, Neuroscience

21. mai 2025, 17:23 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

Medtronic to Separate Diabetes Business as Stand-Alone Company -- 2nd Update

21. mai 2025, 11:39 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

Medtronic to Separate Diabetes Business as Stand-Alone Company -- Update

21. mai 2025, 10:52 UTC

Tulu

Medtronic Sees FY26 Adjusted EPS Up About 4% Excluding Potential Impacts From Increased Tariffs >MDT

21. mai 2025, 10:51 UTC

Tulu

Medtronic Sees FY26 Adj EPS $5.50-Adj EPS $5.60, Including Potential Tariff Impact >MDT

21. mai 2025, 10:50 UTC

Tulu

Medtronic Sees FY26 Reported Revenue Up 4.8%-5.1% if Recent Forex Rates Hold >MDT

21. mai 2025, 10:49 UTC

Tulu

Medtronic Sees FY26 Organic Revenue Growth Up About 5% >MDT

21. mai 2025, 10:49 UTC

Tulu

Medtronic Names Michael Carter Sr VP, President of Cranial, Spinal Technologies >MDT

21. mai 2025, 10:48 UTC

Tulu

Medtronic Names Skip Kiil Exec VP, President of Cardiovascular Portfolio >MDT

21. mai 2025, 10:48 UTC

Tulu

Medtronic: Sean Salmon, Exec VP and President of, Cardiovascular Portfolio Leaving >MDT

21. mai 2025, 10:47 UTC

Tulu

Medtronic Raises Quarterly Dividend to 71c From 70c >MDT

21. mai 2025, 10:45 UTC

Omandamised, ülevõtmised, äriostud

Medtronic: Preferred Path of Initial Public Offering, Subsequent Split-Off >MDT

21. mai 2025, 10:45 UTC

Tulu

Medtronic Reports Strong Finish To Its Fiscal Year With Its Fourth Quarter Financial Results; Announces Dividend Increase >MDT

21. mai 2025, 10:45 UTC

Tulu

Medtronic 4Q Net $1.06B >MDT

21. mai 2025, 10:45 UTC

Tulu

Medtronic 4Q Medical Surgical Portfolio Rev $2.21B >MDT

21. mai 2025, 10:45 UTC

Tulu

Medtronic 4Q Neuroscience Portfolio Rev $2.62B >MDT

21. mai 2025, 10:45 UTC

Tulu

Medtronic 4Q Diabetes Rev $728M >MDT

21. mai 2025, 10:45 UTC

Tulu

Medtronic 4Q Organic Revenue Up 5.4% >MDT

21. mai 2025, 10:45 UTC

Tulu

Medtronic 4Q Adj EPS $1.62 >MDT

21. mai 2025, 10:45 UTC

Tulu

Medtronic 4Q EPS 82c >MDT

21. mai 2025, 10:45 UTC

Tulu

Medtronic 4Q Cardiovascular Portfolio Rev $3.34B >MDT

21. mai 2025, 10:45 UTC

Tulu

Medtronic 4Q Sales $8.93B >MDT

21. mai 2025, 09:00 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

Medtronic to Separate Diabetes Business as Stand-Alone Company -- WSJ

21. mai 2025, 09:00 UTC

Omandamised, ülevõtmised, äriostud

Medtronic to Separate Diabetes Business, Sources Say -- WSJ

21. mai 2025, 09:00 UTC

Omandamised, ülevõtmised, äriostud

Medtronic's Separation of Diabetes Business to Finish Within 18 Months, Sources Say -- WSJ

21. mai 2025, 09:00 UTC

Omandamised, ülevõtmised, äriostud

Medtronic Diabetes Business Sales Totaled Nearly $2.5B in 2024 -- WSJ

27. veebr 2025, 10:30 UTC

Peamised uudised

Squeezed by Strong Dollar, Companies Try to Neutralize Currency Swings -- WSJ

18. veebr 2025, 11:47 UTC

Tulu

Medtronic: Will Accelerate Top-, Bottom-Line Growth in 4Q >MDT

18. veebr 2025, 11:46 UTC

Tulu

Medtronic Still Sees FY25 Organic Revenue Growth 4.75%-5% >MDT

Võrdlus sarnastega

Hinnamuutus

Medtronic PLC Prognoos

Hinnasiht

By TipRanks

10.07% tõus

12 kuu keskmine prognoos

Keskmine 95.76 USD  10.07%

Kõrge 109 USD

Madal 87 USD

Põhineb 21 Wall Streeti analüütiku instrumendi Medtronic PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

21 ratings

11

Osta

10

Hoia

0

Müü

Tehniline skoor

By Trading Central

83.26 / 84.875Toetus ja vastupanu

Lühikene perspektiiv

Weak Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

68 / 380 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.